These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 23148186)
1. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Lomonaco R; Chen J; Cusi K Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186 [TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Lomonaco R; Sunny NE; Bril F; Cusi K Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465 [TBL] [Abstract][Full Text] [Related]
3. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197 [No Abstract] [Full Text] [Related]
4. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
5. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
7. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Ranjbar G; Mikhailidis DP; Sahebkar A Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448 [TBL] [Abstract][Full Text] [Related]
8. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. Portillo-Sanchez P; Cusi K Clin Diabetes Endocrinol; 2016; 2():9. PubMed ID: 28702244 [TBL] [Abstract][Full Text] [Related]
9. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
16. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019 [TBL] [Abstract][Full Text] [Related]
17. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954 [TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Fatty Liver Disease in South Asia. Pati GK; Singh SP Euroasian J Hepatogastroenterol; 2016; 6(2):154-162. PubMed ID: 29201749 [TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879 [TBL] [Abstract][Full Text] [Related]